U24AG072122

National Alzheimer's Coordinating Center - Project Summary

The COVID-19 pandemic has had a substantial impact on vulnerable aging populations across the world. Clinical care of patients with Alzheimer's associated dementia are especially vulnerable to the effects of COVID-19, and COVID-19 has been associated with poor outcomes in patients.

In this National Alzheimer's Coordinating Center (NACC) administrative supplement proposal, we are providing the infrastructure for investigating the genetic factors associated with poor outcomes in patients with AD and a history of COVID-19. We are leveraging and deploying new data collection instruments for COVID-19 phenotypes to the Alzheimer's Disease Research Centers Consortium (ADRCS). This work will provide a high impact, innovative, and economical demonstration of the use of routine clinical care data to quantitatively and accurately phenotype patients.

Care data in the form of Centers for Medicare and Medicaid Services (CMS) administrative claims and electronic health record (EHR) will be the basis for this demonstration. NACC will collaborate with NIAGADS and three pilot sites, Washington University St. Louis, Columbia University, and Indiana University ADRCS.

This work will be done in three aims. First, we will support additional clinical research at the pilot clinical sites and will deploy new prospective data collection instruments to support post-acute sequelae of COVID-19. Second, we will assess feasibility of and begin to collect EHR and CMS data in partnership with the ADRC pilot sites and the NIA. Finally, we will collaborate with NIAGADS to enable collaborative analysis of integrated phenotype and genetic data of enrolled participant data.

Together, this proposal, if funded, will place important infrastructure for the study of AD associated phenotypes and COVID-19.

University Of Washington

TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.866 - Aging Research

National Institute on Aging (NIA) [HHS - NIH]

Seattle, Washington 981056367 United States

Single Zip Code

National Alzheimers Coordinating Center (U24 Clinical Trial Not Allowed) (RFA-AG-21-014)

Amendment Since initial award the total obligations have increased 557% from $6,979,612 to $45,845,722.